Table 2.
Comparison of tissue-based and cfDNA-based mutation tests. (A) Comparison of plasma and tissue BRAFV600 mutation test results, and (B) comparison of BRAF and NRAS plasma mutation tests results in the mITT population. Grey-shaded cells designate the discordance between the respective tests. cfDNA, cell-free DNA; mITT, modified intention-to-treat.
| A. BRAF | Plasma cfDNA Test Result | |||
|---|---|---|---|---|
| Wild-Type | Mutant | |||
| Tissue test result | Wild-type | 111 | 7 | Patients with wild-type tissue test = 118 |
| Mutant | 19 | 35 | Patients with mutant tissue test = 54 | |
| Patients with wild-type plasma test = 130 | Patients with mutant plasma test = 42 | |||
| B. Plasma | BRAF cfDNA test result | |||
| Wild-type | Mutant | |||
| NRAS cfDNA test result | Wild-type | 107 | 42 | Patients with wild-type NRAS = 149 |
| Mutant | 22 | 0 | Patients with mutant NRAS = 22 | |
| Patients with wild-type plasma test = 129 | Patients with mutant plasma test = 42 | |||